ClinicalTrials.gg
CompletedNCT04864912Updated Mar 7, 2025Results posted

Retrospective Health Care Utilisation and Current Quality of Life in Adults With Chronic Otitis Media Who Had a Middle Ear Surgery

An observational study in Chronic Otitis Media, sponsored by Cochlear. Completed at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-07.

Sponsored by Cochlear · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
69
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this multicentre study is to evaluate the standard of care of participants diagnosed with Chronic Otitis Media that have already gone through a first middle ear surgery but still have at least a moderate hearing loss. The study has a retrospective part (extraction of medical chart data) and a prospective part with a survey and three questionnaires collecting data on the use of health care services, on health related quality of life and hearing performance.

02

Conditions studied

  • Chronic Otitis Media

Browse trials for

Keywords

  • Primary tympanoplasty
03

In context

Otitis Media

241 studies on the registry are indexed under Otitis Media; 32 are open to participants now.

This study's enrollment of 69 is below the median of 150 across 57 observational studies indexed under Otitis Media.

Browse Otitis Media studies →

Lead sponsor

Cochlear is the lead sponsor of 92 studies on the registry; 9 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult participants with a history of chronic otitis media who have undergone a primary tympanoplasty to improve hearing between 2010-2016 but still have conductive or mixed hearing loss.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subjects, 18 years or older.
  • Subjects with conductive or mixed hearing loss.
  • Subjects with historically documented diagnosis of Chronic Otitis Media (COM) with or without cholesteatoma in the operated ear.
  • Subjects who have undergone primary tympanoplasty type I-V to improve hearing between 2010-2016.
  • Subjects with a Pure Tone Average (PTA)4 air-bone gap ≥30 decibels (dB) OR PTA4 air-bone gap between 25-30 dB with an air conduction threshold PTA4 ≥40 dB HL within 12 months after primary tympanoplasty in the operated ear.
  • Subjects who have been recommended by their health care professional to try a hearing aid to improve hearing in the operated ear.
  • Pre-op audiogram, maximum 1 year prior to the primary tympanoplasty, and post-op audiogram for the primary tympanoplasty are available.
  • Aided audiogram, unaided if no hearing device is used, available between 2018 and the point of enrolment.
  • Subjects are fluent in the language used for study questionnaires: German, French, Spanish.
  • Subjects are willing and able to provide written . For France: subjects do not oppose to participate in the study.
  • Medical Record data is available throughout the defined data search period, from primary tympanoplasty to point of enrolment.

Exclusion criteria

Exclusion Criteria:

  • Subjects are unable or unwilling to comply with the requirements of the study as determined by the investigator.
  • Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling.
  • Cochlear employees or employees of Contract Research Organizations or contractors engaged by Cochlear for the purposes of this study.

For France only:

  • Subjects who are not affiliated to social security.
  • Subjects who are under legal protection.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
69 participants (actual)
Patient registry
No

Interventions

  • OtherQuestionnaires and survey

    Questionnaires: Health Utilities Index Mark III, Chronic Otitis Media Outcome Test-15 and Speech, Spatial, and Qualities of Hearing Scale-12 Survey: Client Service Receipt Inventory (adapted version)

06

What researchers measure

Primary outcomes

  1. Number and Type of Contacts With Health Care Providers

    Contacts are obtained from medical records, counted and categorized.

    Time frame: From primary tympanoplasty to time of enrolment, up to 13 years

  2. Number and Type of Interventions and/or Procedures

    Medical examinations, surgical procedures and hearing rehabilitation are obtained from medical records, counted and categorized.

    Time frame: From primary tympanoplasty to time of enrolment, up to 13 years

  3. Number and Type of Medications and Therapies

    Medications are obtained from medical records, counted and categorized. Therapies from medical records are listed.

    Time frame: From primary tympanoplasty to time of enrolment, up to 13 years

Secondary outcomes

  1. Hearing Performance Assessed Via an Audiogram

    PTA4 (0.5, 1, 2 and 4 kHz) for both air and bone conduction, under unaided and when applicable aided conditions. Data obtained from participant medical records.

    Time frame: Up to 12 months prior to primary tympanoplasty

  2. Hearing Performance Assessed Via an Audiogram

    PTA4 (0.5, 1, 2 and 4 kHz) for both air and bone conduction, under unaided and when applicable aided conditions. Data obtained from participant medical records.

    Time frame: Within 12 months after primary tympanoplasty

  3. Hearing Performance Assessed Via an Audiogram

    PTA4 (0.5, 1, 2 and 4 kHz) for both air and bone conduction, under unaided and when applicable aided conditions. Data obtained from participant medical records.

    Time frame: Up to 6 years prior to study enrollment

  4. Health Care Costs

    Direct medical costs were calculated by applying the reported Diagnosis Related Group (DRG) codes for Chronic Otitis Media related health care utilization were obtained to the unit cost in each participating country for each participant. Note: No outcome measures are reported as there was insufficient data collection

    Time frame: From primary tympanoplasty to time of enrolment.

  5. Socio-economic Status and Health Care Data Via the Client Service Receipt Inventory (CSRI) Survey

    Demographic data, medical history, hearing rehabilitation, health care utilisation related to ear infection and hearing difficulties and employment information data are collected.

    Time frame: At enrolment

  6. Self-reported Health Status and Health Related Quality of Life Via the Health Utilities Index Mark III (HUI3) Questionnaire.

    HUI provides descriptive evidence on multiple dimensions of health status, a score for each dimension of health and an overall Health Related Quality of life score. The HUI3 classification system is comprised of 8 attributes: Vision, Hearing, Speech, Ambulation, Dexterity, Emotion, Cognition and Pain - each with 5 or 6 levels of ability/disability The scoring systems provide utility (preference) scores on a generic scale where 0.00 indicates death and 1.00 indicates perfect health.

    Time frame: At enrolment

  7. Self-reported Health Related Quality of Life of Participants With COM Via the Chronic Otitis Media Outcome Test-15 (COMOT-15) Questionnaire.

    COMOT-15 measures Health Related Quality of life of participants with COM. It consists of three subscales: ear symptoms, hearing function, and mental health forming the overall score. In addition, two questions related to COM are asked: one on the general evaluation of quality of life and one on the frequency of doctor visits in the last six months. The total score and the sub-scores are transformed to a 0-100 scale by dividing the sum of the raw scores of the items by the sum of spans of the items, then multiplying by 100. A higher score indicates a worse health-related quality of life.

    Time frame: At enrolment

  8. Self-reported Auditory Disability Via the Speech, Spatial and Qualities of Hearing Scale (SSQ-12) Questionnaire

    SSQ-12 measures speech, spatial and hearing experiences. The total(overall) score summarizes these parameters. A scale from 0 to 10 is used. A mark 0 means "be quite unable to do or experience what is described" and a mark 10 means "be perfectly able to do or experience what is described in the question".

    Time frame: At enrolment

  9. Chronic Otitis Media Outcome Test -15 (COMOT-15) Questionnaire in German, French and Spanish

    Mean score of Chronic Otitis Media Outcome Test -15 (COMOT-15) in German, French and Spanish (0-100 scale). This questionnaire consists of 15 questions that query 3 subscales: ear symptoms, hearing function, and mental health. Additionally, it includes a question about quality of life and specialist doctor visit frequency. The total score is summed, transformed and presented on a 0 - 100 scale where 0 is a good outcome and 100 is the worst possible outcome.

    Time frame: At enrollment

07

Results

Posted Mar 7, 2025

Participant flow

Participant flow — Overall Study
MilestoneObservational Cohort
Started69
Completed69
Not completed0

Outcome measures

PrimaryNumber and Type of Contacts With Health Care Providers

Contacts are obtained from medical records, counted and categorized.

Time frame:
From primary tympanoplasty to time of enrolment, up to 13 years
Reported as:
Count of participants · Participants
Number and Type of Contacts With Health Care Providers
ParticipantsObservational Cohort
Contact for 1 surgical procedure45
Contact for 2 surgical procedures14
Contact for 3 surgical procedures5
Contact for 4 surgical procedures3
Contact for more than four surgical procedures2
Contact for 2 audiograms45
Contact for 3 audiograms5
Contact for 4 audiograms3
Contact for more than four audiograms16
1 other healthcare contacts5
2 other healthcare contacts1
3 other healthcare contacts4
4 other healthcare contacts7
More than 4 other healthcare contacts36
PrimaryNumber and Type of Interventions and/or Procedures

Medical examinations, surgical procedures and hearing rehabilitation are obtained from medical records, counted and categorized.

Time frame:
From primary tympanoplasty to time of enrolment, up to 13 years
Reported as:
Count of participants · Participants
Number and Type of Interventions and/or Procedures
ParticipantsObservational Cohort
CT scan of the temporal bone and/or sinuses12
MRI of the temporal bone or the brain23
another medical examination14
primary tympanoplasty65
revision surgeries25
planned staged or second look surgeries18
PrimaryNumber and Type of Medications and Therapies

Medications are obtained from medical records, counted and categorized. Therapies from medical records are listed.

Time frame:
From primary tympanoplasty to time of enrolment, up to 13 years
Reported as:
Count of participants · Participants
Number and Type of Medications and Therapies
ParticipantsObservational Cohort
Antiinfective20
Analgesics and anesthetics1
Anilides14
Antivertigo preparations3
Benzodiazepine derivatives1
Combinations of penicillins, incl. beta-lactamase inhibitors4
Corticosteroids5
Corticosteroids and antiinfectives in combination12
Fluoroquinolones3
Glucocorticoids5
Macrolides1
Other otologicals2
Other cicatrizants1
Other opioids6
Penicillins with extended spectrum2
Pyrazolones2
SecondaryHearing Performance Assessed Via an Audiogram

PTA4 (0.5, 1, 2 and 4 kHz) for both air and bone conduction, under unaided and when applicable aided conditions. Data obtained from participant medical records.

Time frame:
Up to 12 months prior to primary tympanoplasty
Reported as:
Mean · db HL (decibel hearing loss)
Hearing Performance Assessed Via an Audiogram
db HL (decibel hearing loss)Observational Cohort
Air Conduction53.2 ± 19.64
Bone Conduction23.8 ± 14.76
SecondaryHearing Performance Assessed Via an Audiogram

PTA4 (0.5, 1, 2 and 4 kHz) for both air and bone conduction, under unaided and when applicable aided conditions. Data obtained from participant medical records.

Time frame:
Within 12 months after primary tympanoplasty
Reported as:
Mean · db HL (decibel hearing loss)
Hearing Performance Assessed Via an Audiogram
db HL (decibel hearing loss)Observational Cohort
Air Conduction58.7 ± 14.9
Bone conduction25.3 ± 14.85
SecondaryHearing Performance Assessed Via an Audiogram

PTA4 (0.5, 1, 2 and 4 kHz) for both air and bone conduction, under unaided and when applicable aided conditions. Data obtained from participant medical records.

Time frame:
Up to 6 years prior to study enrollment
Reported as:
Mean · db HL (decibel hearing loss)
Hearing Performance Assessed Via an Audiogram
db HL (decibel hearing loss)Observational Cohort
Air conduction56.7 ± 21.16
Bone conduction25.2 ± 13.89
SecondaryHealth Care Costs

Direct medical costs were calculated by applying the reported Diagnosis Related Group (DRG) codes for Chronic Otitis Media related health care utilization were obtained to the unit cost in each participating country for each participant. Note: No outcome measures are reported as there was insufficient data collection

Time frame:
From primary tympanoplasty to time of enrolment.

No measurements were reported for this outcome.

SecondarySocio-economic Status and Health Care Data Via the Client Service Receipt Inventory (CSRI) Survey

Demographic data, medical history, hearing rehabilitation, health care utilisation related to ear infection and hearing difficulties and employment information data are collected.

Time frame:
At enrolment
Reported as:
Count of participants · Participants
Socio-economic Status and Health Care Data Via the Client Service Receipt Inventory (CSRI) Survey
ParticipantsObservational Cohort
married/living as married41
single14
widowed7
divorced/separated6
living with spouse/partner and children24
living with spouse/partner without children19
living alone13
living with their parents6
lived in other conditions6
place of residence was an owner occupied flat/house44
place of residence was a privately rented flat/house15
place of residence was a flat/house rented from a local authority or housing association4
other places of residence5
highest level of education was university or higher20
highest level of education was high school19
highest level of education was vocational training17
highest level of education was primary school12
high blood pressure12
autoimmune disease4
cancer1
heart disease5
diabetes4
chronic lung disease4
chronic kidney disease2
mood disorders8
substance dependency1
other chronic disease13
never smoked39
current smokers16
previous smokers13
full-time employment31
retired20
part-time employment5
retired (because of ill health), unemployed, student or housewife/husband2
self-employed1
currently use a hearing aid or hearing device31
bone conduction implant7
visited a general practitioner21
attended a day hospital or accident and emergency2
visited an ENT31
Visited audiologist14
SecondarySelf-reported Health Status and Health Related Quality of Life Via the Health Utilities Index Mark III (HUI3) Questionnaire.

HUI provides descriptive evidence on multiple dimensions of health status, a score for each dimension of health and an overall Health Related Quality of life score. The HUI3 classification system is comprised of 8 attributes: Vision, Hearing, Speech, Ambulation, Dexterity, Emotion, Cognition and Pain - each with 5 or 6 levels of ability/disability The scoring systems provide utility (preference) scores on a generic scale where 0.00 indicates death and 1.00 indicates perfect health.

Time frame:
At enrolment
Reported as:
Mean · score on a scale
Self-reported Health Status and Health Related Quality of Life Via the Health Utilities Index Mark III (HUI3) Questionnaire.
score on a scaleObservational Cohort
Overall0.7 ± 0.28
Vision0.9 ± 0.17
Hearing0.8 ± 0.29
Speech0.9 ± 0.15
Dexterity1 ± 0.11
Emotion0.9 ± 0.16
Cognition0.9 ± 0.14
Pain0.9 ± 0.19
SecondarySelf-reported Health Related Quality of Life of Participants With COM Via the Chronic Otitis Media Outcome Test-15 (COMOT-15) Questionnaire.

COMOT-15 measures Health Related Quality of life of participants with COM. It consists of three subscales: ear symptoms, hearing function, and mental health forming the overall score. In addition, two questions related to COM are asked: one on the general evaluation of quality of life and one on the frequency of doctor visits in the last six months. The total score and the sub-scores are transformed to a 0-100 scale by dividing the sum of the raw scores of the items by the sum of spans of the items, then multiplying by 100. A higher score indicates a worse health-related quality of life.

Time frame:
At enrolment
Reported as:
Mean · units on a scale
Self-reported Health Related Quality of Life of Participants With COM Via the Chronic Otitis Media Outcome Test-15 (COMOT-15) Questionnaire.
units on a scaleObservational Cohort
Overall43 ± 18.25
Ear symptoms29.4 ± 20.28
Hearing function65 ± 22.84
Mental Health46.5 ± 27.31
SecondarySelf-reported Auditory Disability Via the Speech, Spatial and Qualities of Hearing Scale (SSQ-12) Questionnaire

SSQ-12 measures speech, spatial and hearing experiences. The total(overall) score summarizes these parameters. A scale from 0 to 10 is used. A mark 0 means "be quite unable to do or experience what is described" and a mark 10 means "be perfectly able to do or experience what is described in the question".

Time frame:
At enrolment
Reported as:
Mean · score on a scale
Self-reported Auditory Disability Via the Speech, Spatial and Qualities of Hearing Scale (SSQ-12) Questionnaire
score on a scaleObservational Cohort
Self-reported Auditory Disability Via the Speech, Spatial and Qualities of Hearing Scale (SSQ-12) Questionnaire5.5 ± 2.18
SecondaryChronic Otitis Media Outcome Test -15 (COMOT-15) Questionnaire in German, French and Spanish

Mean score of Chronic Otitis Media Outcome Test -15 (COMOT-15) in German, French and Spanish (0-100 scale). This questionnaire consists of 15 questions that query 3 subscales: ear symptoms, hearing function, and mental health. Additionally, it includes a question about quality of life and specialist doctor visit frequency. The total score is summed, transformed and presented on a 0 - 100 scale where 0 is a good outcome and 100 is the worst possible outcome.

Time frame:
At enrollment
Reported as:
Mean · score on a scale (0-100)
Chronic Otitis Media Outcome Test -15 (COMOT-15) Questionnaire in German, French and Spanish
score on a scale (0-100)Observational Cohort
German36.8 ± 14.76
French46.3 ± 22.73
Spanish45 ± 17.12

Adverse events

Collected over Not applicable. Survey administered at a single timepoint and retrospective chart review design.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Observational Cohort———

Baseline characteristics

Age, Continuous
Age, Continuous(years)Observational Cohort
Mean50.8 ± 18.08
Sex: Female, Male
Sex: Female, Male(Participants)Observational Cohort
Female37
Male32
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Observational Cohort
Diabetes
Diabetes(participants)Observational Cohort
No65
Yes4
Turner Syndrome
Turner Syndrome(participants)Observational Cohort
No69
Yes0
Cleft Palate
Cleft Palate(participants)Observational Cohort
No69
Yes0
Down Syndrome
Down Syndrome(participants)Observational Cohort
No69
Yes0
Cholesteatoma
Cholesteatoma(participants)Observational Cohort
No33
Yes36
08

Study locations

6 sites
  • Hôpital Bicêtre, Hôpitaux universitaires Paris Sud AP-HP
    Le Kremlin-Bicêtre, 94275, France
  • ENT department - Bâtiment Pierre Paul Riquet - Hôpital Purpan
    Toulouse, 31059, France
  • Universitätsklinik für Hals-, Nasen und Ohrenheilkunde
    Freiburg, 79106, Germany
  • Hals-, Nasen- und Ohrenklinik, Universitätsklinikum Heidelberg
    Heidelberg, 69120, Germany
  • Hospital Universitario Donostia
    Donostia, 20080, Spain
  • Hospital Universitario Virgen Macarena
    Sevilla, 41009, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Cochlear do not have an approved platform for public sharing of IPD collected in this study. Data may be provided to individual researchers on request.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Oct 2023, 20 months.

Results were first posted in Mar 2025, 1 year 4 months after primary completion.

Of 22 observational studies under Otitis Media, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 67. This study's 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2021
First posted
Apr 29, 2021
StartActual
Feb 1, 2022
Primary completionActual
Oct 9, 2023
CompletionActual
Oct 9, 2023
Results first posted
Mar 7, 2025
Last update
Mar 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04864912
Lead sponsor
Cochlear
Collaborators
QbD Clinical, Suministros Hospitalarios Medical Group
Responsible party
Sponsor
First posted
Apr 29, 2021
Start date
Feb 1, 2022
Primary completion
Oct 9, 2023
Completion
Oct 9, 2023
Results posted
Mar 7, 2025
Last update
Mar 7, 2025

Study contacts

Christiane D'hondt
study director · Cochlear

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion